Allogene Therapeutics (ALLO) Total Current Liabilities (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Total Current Liabilities data on file, last reported at $28.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 5.64% year-over-year to $28.3 million; the trailing twelve-month figure through Mar 2026 stood at $28.3 million (down 5.64% YoY), and the FY2025 full-year result was $32.5 million, down 8.47% from the prior year.
• Total Current Liabilities fell to $28.3 million in Q1 2026, from $32.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $59.4 million in Q1 2023 to a low of $28.3 million in Q1 2026.
• A 5-year average of $38.9 million and a median of $36.6 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 62.21% in 2023 and plunged 47.99% in 2024, its largest moves.
• Tracing ALLO's Total Current Liabilities over 5 years: stood at $53.7 million in 2022, then slumped by 30.99% to $37.1 million in 2023, then declined by 4.2% to $35.5 million in 2024, then decreased by 8.47% to $32.5 million in 2025, then slipped by 12.87% to $28.3 million in 2026.
• Business Quant data shows ALLO's Total Current Liabilities at $28.3 million in Q1 2026, $32.5 million in Q4 2025, and $31.8 million in Q3 2025.